中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

22 records (took 0.023 seconds)

    11.
    发明专利
    未知

    公开(公告)号：AT233747T

    公开(公告)日：2003-03-15

    申请号：AT99125083

    申请日：1999-12-16

    Applicant: BASF AG

    Inventor： RIECHERS HARTMUT DR ,  SIMON JOACHIM DR ,  HENNE ANDREAS DR ,  HOEHN ARTHUR DR

    IPC: C07D295/08 ,  B01J23/72 ,  C07D295/088

    Abstract: 2,2'-Dimorpholinodiethyl ether is produced by reacting diethylene glycol with ammonia under pressure at elevated temperature in the presence of hydrogen. The active hydrogenation catalyst, before reduction with hydrogen, contains 20-85 wt.% alumina, zirconium dioxide, titanium dioxide and/or silica, 1-70 wt.% copper oxide (CuO), less than 20 wt.% nickel oxide with respect to CuO and 0-50 wt.% other metal oxide(s). In the production of 2,2'-dimorpholinodiethyl ether (DMDEE) by reacting diethylene glycol with ammonia under pressure at elevated temperature in the presence of hydrogen and a hydrogenation catalyst, the active catalyst, before reduction with hydrogen, contains 20-85 wt.% aluminum oxide (Al2O3), zirconium dioxide (ZrO2), titanium dioxide (TiO2) and/or silica (SiO2), 1-70 wt.% copper oxide (expressed as CuO), 0-50 wt.% magnesium, chromium, zinc, barium and/or calcium oxide (expressed as MgO, Cr2O3, ZnO, BaO and CaO) and less than 20 wt.% nickel oxide (expressed as NiO) with respect to CuO.

    New carbocyclic and heterocyclic carboxylic acid or tetrazolyl compounds
    19.
    发明专利
    New carbocyclic and heterocyclic carboxylic acid or tetrazolyl compounds 未知

    公开(公告)号：DE19652763A1

    公开(公告)日：1998-06-25

    申请号：DE19652763

    申请日：1996-12-18

    Applicant: BASF AG

    Inventor： AMBERG WILHELM DR ,  JANSEN ROLF DR ,  KLING ANDREAS DR ,  KLINGE DAGMAR DR ,  RIECHERS HARTMUT DR ,  HERGENROEDER STEFAN DR ,  RASCHACK MANFRED DR ,  UNGER LILIANE DR

    IPC: C07D237/14 ,  C07D237/16 ,  C07D241/18 ,  C07D253/07 ,  C07D253/075 ,  C07D253/10 ,  C07D491/04 ,  A61K31/195 ,  A61K31/53 ,  C07D241/14 ,  C07D241/36 ,  C07D255/00 ,  C07D487/06 ,  C07D493/04 ,  C07D495/04

    Abstract: Heterocyclic compounds of formula (I) and their salts are new. R1 = tetrazolyl, or COR; R = OR6, O(CH2)pS(O)kR7, NHS(O)2R8 or a 5-membered azaheteroaryl; R2 = 1-4C alkyl, 2-4C alkenyl, 2-4C alkynyl (all optionally substituted), H, halo, 1-4C alkoxy, 1-4C haloalkoxy, 3-6C alkenyloxy, 3-6C alkynyloxy, 1-4C alkylthio, 1-4C alkylcarbonyl, 1-4C alkoxycarbonyl, NH(1-4C alkyl), N(1-4C alkyl)2, OH, carboxy or amino; R3, R4 = phenyl, naphthyl or 3-8C cycloalkyl (all optionally substituted); or R3+R4 = two of phenyl, naphthyl linked at the o-position by a bond, methylene, ethylene, ethenyl, S, SO2, NH or N-alkyl; R5 = H, 1-8C alkyl, 3-8C alkenyl, 3-8C alkynyl, Ph, naphthyl, 5-6 membered heteroaromatic (containing 1-3 N, S and/or O), or 3-8C cycloalkyl (all optionally substituted); R6 = H, alkali metal or earth-alkali metal, organic ammonium, 3-8C cycloalkyl, 1-8C alkyl, or (all optionally substituted) benzyl, 3-8C alkenyl, 3-8C alkynyl or phenyl; R7 = 1-4C alkyl, 3-8C cycloalkyl, 3-8C alkenyl, 3-8C alkynyl or optionally substituted phenyl; R8 = 1-4C alkyl, 3-8C alkenyl, 3-8C alkynyl, 3-8C cycloalkyl (all optionally substituted by 1-4C alkoxy, 1-4C alkylthio and/or phenyl), 1-4C haloalkyl or optionally substituted phenyl; X = N, Y = N or CR9 and Z = N; or X = CH, Y = N or CR9 and Z = N or CR10 provided that Y or Z = N; R9, R10 = 1-4C alkyl, 2-4C alkenyl or 2-4C alkynyl (all optionally substituted), H, OH, NH2, NH(1-4C alkyl), N(1-4C alkyl)2, halo, 1-4C alkoxy, 1-4C haloalkoxy or 1-4C alkylthio; or CR2+CR9 or CR2+CR10 completes a 5-6 membered alkylene or alkenyl ring (optionally substituted) with one or more CH2 optionally replaced by O, S, NH or N(1-4C alkyl); Q = N and W = bond; or Q = O and W = S, O or a bond; k = 0-2; and p = l-4.

    20.
    发明专利
    未知

    公开(公告)号：DE19636046A1

    公开(公告)日：1998-03-12

    申请号：DE19636046

    申请日：1996-09-05

    Applicant: BASF AG

    Inventor： AMBERG WILHELM DR ,  JANSEN ROLF DR ,  KLING ANDREAS DR ,  KLINGE DAGMAR DR ,  RIECHERS HARTMUT DR ,  HERGENROEDER STEFAN DR ,  RASCHACK MANFRED DR ,  UNGER LILIANE DR

    IPC: A61K31/505 ,  A61K31/506 ,  A61K31/519 ,  A61P9/04 ,  A61P9/08 ,  A61P9/12 ,  A61P43/00 ,  C07C59/66 ,  C07C69/734 ,  C07D239/34 ,  C07D239/52 ,  C07D239/60 ,  C07D239/70 ,  C07D491/04 ,  C07D491/048 ,  C07D405/10 ,  C07D403/12 ,  C07D251/12 ,  C07C59/64 ,  A61K31/41

    Abstract: Carboxylic acid derivatives have the formula (I), in which R stands for tetrazole or a group (a); R stands for hydrogen, hydroxy, NH2, NH(C1-c4-alkyl), N(C1-C4-alkyl)2, halogen, C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkinyl, C1-C4-alkyl halide, C1-C4-alkoxy, C1-C4-alkoxy halide or C1-C4-alkylthio, or CR is linked with CR , as indicated below, into a 5- or 6-membered ring; X stands for nitrogen or methine; Y stands for nitrogen or methine; Z stands for nitrogen or CR , wherein R is hydrogen or C1-C4-alkyl or CR forms together with CR or CR an optionally substituted 5- or 6-membered alkylene or alkenylene ring, and wherein one or more methylene groups can be substituted by hydrogen, sulphur, -NH or -N(C1-C4-alkyl); R stands for hydrogen, hydroxy, NH2, NH(C1-C4-alkyl), N(C1-C4-alkyl)2, halogen, C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkinyl, C1-C4-hydroxyalkyl, C1-C4-alkyl halide, C1-C4-alkoxy, C1-C4-alkoxy halide, C1-C4-alkylthio; or CR is linked to CR as indicated above into a 5- or 6-membered ring, R and R (which may be identical or different) stand for optionally substituted phenyl or naphthyl, or for phenyl or naphthyl which are linked to each other at the ortho-position by a direct bond, a methylene, ethylene or ethenylene group, an oxygen or sulphur atom or an SO2, NH or N-alkyl group; optionally substituted C3-C8-cycloalkyl; R stands for optionally substituted C3-C8-cycloalkyl; optionally substituted phenyl or naphthyl, a 5- or 6-membered, optionally substituted heteroaromatic compound containing one to three nitrogen atoms and/or one sulphur or oxygen atom; W stands for sulphur or oxygen; Q is a spacer with a length that corresponds to a C2-C4 chain. Also disclosed are the physiologically tolerable salts of these compounds, as well as their pure enantiomer and diastereoisomer forms, their preparation and use as mixed ETA/ETB-receptor antagonists.

Patent Agency Ranking